Female Health Company (The) (NASDAQ:VERU) has been assigned a $5.00 price target by research analysts at HC Wainwright in a research note issued to investors on Tuesday. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 309.84% from the stock’s current price.
Several other equities research analysts have also commented on VERU. ValuEngine lowered shares of Female Health Company (The) from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Zacks Investment Research raised shares of Female Health Company (The) from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Wednesday, September 27th. Finally, Rodman & Renshaw started coverage on shares of Female Health Company (The) in a research note on Wednesday, July 26th. They issued a “buy” rating and a $5.00 target price for the company.
Female Health Company (VERU) opened at $1.22 on Tuesday. Female Health Company has a 12 month low of $0.82 and a 12 month high of $3.00.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/14/hc-wainwright-analysts-give-female-health-company-the-veru-a-5-00-price-target.html.
In related news, Director Harry Fisch acquired 34,250 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was bought at an average price of $1.51 per share, with a total value of $51,717.50. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mitchell Shuster Steiner acquired 100,000 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were bought at an average cost of $1.63 per share, with a total value of $163,000.00. Following the purchase, the insider now owns 7,764,767 shares in the company, valued at $12,656,570.21. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 146,975 shares of company stock valued at $234,279. Corporate insiders own 10.90% of the company’s stock.
Female Health Company (The) Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Female Health Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.